Goldman Sachs Group Inc Avadel Pharmaceuticals PLC Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$12.55 - $17.22 $1.42 Million - $1.95 Million	-113,048 Reduced 23.2%	374,203 $6.32 Million
Q4 2023 Feb 13, 2024	BUY	$9.64 - $14.59 $1.21 Million - $1.84 Million	125,799 Added 34.8%	487,251 $6.88 Million
Q3 2023 May 14, 2024	SELL	$10.3 - $15.99 $1.3 Million - $2.01 Million	-125,799 Reduced 25.82%	361,452 $3.72 Million
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $1.53 Million - $2.38 Million	148,653 Added 69.86%	361,452 $3.72 Million
Q2 2023 May 14, 2024	BUY	$8.48 - $16.48 $1.36 Million - $2.64 Million	160,431 Added 306.35%	212,799 $3.51 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $1.36 Million - $2.64 Million	160,431 Added 306.35%	212,799 $3.51 Million
Q1 2023 May 14, 2024	BUY	$6.41 - $9.95 $154,160 - $239,297	24,050 Added 84.93%	52,368 $479,000
Q1 2023 May 11, 2023	BUY	$6.41 - $9.95 $154,160 - $239,297	24,050 Added 84.93%	52,368 $479,000
Q4 2022 May 14, 2024	SELL	$5.02 - $10.0 $15,692 - $31,260	-3,126 Reduced 9.94%	28,318 $202,000
Q4 2022 Feb 13, 2023	SELL	$5.02 - $10.0 $15,692 - $31,260	-3,126 Reduced 9.94%	28,318 $202,000
Q3 2022 May 14, 2024	BUY	$2.57 - $7.31 $27,360 - $77,822	10,646 Added 51.19%	31,444 $158,000
Q3 2022 Nov 10, 2022	BUY	$2.57 - $7.31 $27,360 - $77,822	10,646 Added 51.19%	31,444 $0
Q2 2022 May 14, 2024	SELL	$1.07 - $6.95 $499,104 - $3.24 Million	-466,453 Reduced 95.73%	20,798 $51,000
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $25,838 - $167,828	-24,148 Reduced 53.73%	20,798 $51,000
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $65,831 - $99,952	-12,057 Reduced 21.15%	44,946 $307,000
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $122,240 - $186,191	16,654 Added 41.27%	57,003 $461,000
Q3 2021 Nov 10, 2021	BUY	$6.49 - $9.91 $261,865 - $399,858	40,349 New	40,349 $395,000

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account